Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.


A Novel Multi-Biomarker Disease Activity Score (VectraDA algorithm score) Reflects Clinical Disease Activity Score and Health Assessment Questionnaire for Rheumatoid Arthritis in the BeSt Study.

Hirata1,  Shintaro, Dirven2,  Linda, Cavet3,  Guy, Shen4,  Yijing, Centola5,  Michael, Lems6,  Willem F., Huizinga2,  Tom W.J.

University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan
Leiden University Medical Center, Leiden, Netherlands
Crescendo Bioscience, South San Francisco, CA
Geron Corporation, Menlo Park, CA
Oklahoma Medical Research Foun, Oklahoma City, OK
VU University Medical Center, Amsterdam, Netherlands

Background/Purpose:

Disease activity measurement is the cornerstone of tight control and treat to target strategies, and is recommended by ACR and EULAR guidelines. A novel multi-biomarker based disease activity (MBDA) score has been validated in a broad RA population. However, the utility of the MBDA for evaluating disease activity and for predicting functional disability specifically in very early RA patients has not been investigated.The purpose of the study is to confirm the utility of the MBDA score as a novel disease activity index and as a predictor of Health Assessment Questionnaire (HAQ), in the BeSt study, a cohort of very early RA patients.

Methods:

We analyzed 124 RA patients in the BeSt study. Clinical data and serum samples were available from 180 visits, 91 at baseline (BL) and 89 at year 1. The MBDA score combines 12 serum biomarkers (VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, Leptin, Resistin, CRP, SAA) in a pre-specified algorithm, resulting in a score between 1 and 100. Associations between continuous variables were evaluated by Pearson's correlation. MBDA scores for groups stratified by DAS28 were compared by one-way factorial ANOVA. The association of categorical variables was assessed by Fisher's exact test.

Results:

The MBDA score was correlated to DAS28 (cor = 0.66, p < 0.0001). Similar results were obtained for DAS28CRP, and the original DAS. DMBDA score was also correlated to DDAS28 (cor = 0.54, p < 0.0001). MBDA scores in groups stratified by EULAR disease activity (DAS28 < 3.2, 3.2 to 5.1, and > 5.1) were significantly different (p < 0.0001). MBDA score could discriminate low disease activity (DAS28 < 3.2) with area under ROC curve of 0.83 (P < 0.0001). Correlation between MBDA score and HAQ-DI (cor = 0.51, p < 0.0001), and also DMBDA and DHAQ-DI (cor = 0.47, p = 0.0003) were significant. Furthermore, the group with MBDA low disease activity (MBDA <= 28) at year 1 showed significantly higher ratio of HAQ remission (HAQ-DI <= 0.5) (68.6%) than that of the other group (36.8%; p=0.041).

Conclusion:

The MBDA score reflects current clinical disease activity and can track changes in disease activity over time. In addition to DAS, the MBDA score is associated with HAQ in early RA patients. Furthermore, the MBDA score indicates HAQ remission.

To cite this abstract, please use the following information:
Hirata, Shintaro, Dirven, Linda, Cavet, Guy, Shen, Yijing, Centola, Michael, Lems, Willem F., et al; A Novel Multi-Biomarker Disease Activity Score (VectraDA algorithm score) Reflects Clinical Disease Activity Score and Health Assessment Questionnaire for Rheumatoid Arthritis in the BeSt Study. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :351
DOI:

Abstract Supplement

Meeting Menu

2011 ACR/ARHP